Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-26
2011-07-26
Desai, Anand U (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
07985728
ABSTRACT:
A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (Apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (Apo A-I) synthetic peptide, or combination of an Apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various Apo A-I mimetic peptides, or endogenous Apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous Apo A-I.
REFERENCES:
patent: 4643988 (1987-02-01), Segrest et al.
patent: 4925677 (1990-05-01), Feijen
patent: 5202745 (1993-04-01), Sorin et al.
patent: 5291267 (1994-03-01), Sorin et al.
patent: 5321501 (1994-06-01), Swanson et al.
patent: 5365125 (1994-11-01), Goetting et al.
patent: 5459570 (1995-10-01), Swanson et al.
patent: 5465147 (1995-11-01), Swanson
patent: 5700484 (1997-12-01), Chauffard et al.
patent: 5783600 (1998-07-01), Bisgaier et al.
patent: 5874075 (1999-02-01), Collins et al.
patent: 6124273 (2000-09-01), Drohan et al.
patent: 6376464 (2002-04-01), Dasseux et al.
patent: 6506799 (2003-01-01), Dasseux
patent: 6602854 (2003-08-01), Dasseux et al.
patent: 6692466 (2004-02-01), Chow et al.
patent: 6753313 (2004-06-01), Dasseux et al.
patent: 6831105 (2004-12-01), Dasseux
patent: 6844327 (2005-01-01), Dasseux et al.
patent: 6852760 (2005-02-01), Fine et al.
patent: 6878817 (2005-04-01), Lees et al.
patent: 6881860 (2005-04-01), Luchoomun et al.
patent: 6900177 (2005-05-01), Dasseux et al.
patent: 6960648 (2005-11-01), Bonny
patent: 7273469 (2007-09-01), Chan et al.
patent: 2004/0229794 (2004-11-01), Ryan et al.
patent: 2004/0254120 (2004-12-01), Fogelman et al.
patent: 2004/0266671 (2004-12-01), Fogelman et al.
patent: 2005/0118226 (2005-06-01), Kovacs et al.
patent: 2005/0175666 (2005-08-01), Ding
patent: 2005/0176623 (2005-08-01), Wagle
patent: 2005/0202532 (2005-09-01), Bielicki et al.
patent: 2005/0222029 (2005-10-01), Bartel et al.
patent: 2005/0232981 (2005-10-01), Ben-Sasson
patent: 2009/0081293 (2009-03-01), Katsuyuki et al.
patent: 2009/0081299 (2009-03-01), Hossainy et al.
patent: WO-9736927 (1997-10-01), None
patent: WO-9916408 (1999-04-01), None
patent: WO-03026492 (2003-04-01), None
patent: WO-03096983 (2003-11-01), None
patent: WO-2005041866 (2005-05-01), None
patent: WO-2006047279 (2006-05-01), None
patent: WO-2006100567 (2006-09-01), None
patent: WO-2006100567 (2006-09-01), None
patent: WO-2008048387 (2008-04-01), None
patent: WO-2008048387 (2008-04-01), None
“Arisaph Reports on Promising Results Presented at AHA: Novel APO A-I Mimetic Peptide Significantly Inhibits Atherosclerosis in Preclinical Animal Study”, News Release, Arisaph Pharmaceuticals, Boston, MA, (Nov. 15, 2005), 2 pages.
PCT International Search Report (dated Dec. 5, 2009), International Application No. PCT/US2008/012767, International Filing Date—Nov. 14, 2008, (Whole Document).
Ramprasad, Mysore P., et al., “Sustained-Delivery of an ApolipoproteinE-Peptidomimetic Using Multivesicular Liposomes Lowers Serum Cholesterol Levels”, Journal of Controlled Release, Elsevier, Amsterdam, NL, vol. 79, No. 1-3, Feb. 19, 2002, XP004340926, ISSN: 0168-3659, (pp. 207-218).
Abbott Cardiovascular Systems, Non Final Office Action dated Jun. 1, 2009 for U.S. Appl. No. 11/946,028.
Aragane, K., et al., “ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits”, Journal of Lipid Research, 42, (2001), 480-488.
Batetta, B., et al., “Role of cholesterol ester pathway in the control of cell cycle in human aortic smooth muscle cells”, FASEB Journal, 17, (2003), 746-748.
Chang, T. Y., et al., “Catalysis of ACAT may be completed within the plane of membrane: a working hypothesis”, Journal of Lipid Research, 42, (2001), 1933-1938.
Datta, G., et al., “Aromatic residue position on the nonpolar face of class A amphipathic helical peptides determines biological activity”, Journal of Biological Chemistry, 279(24), (2004), 26509-26517.
Gupta, H., et al., “Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide”, Circulation Research, 97, (2005), 236-243.
Hartgerink, J. D., et al., “Peptide-amphiphile nanofibers: a versatile scaffold for the preparation of self-assembling materials”, PNAS, 99(8), (Apr. 2002), 5133-5138.
Hartgerink, J. D., et al., “Self-assembly and mineralization and peptide-amphiphile nanofibers”, Science, www.sciencemag.org, 294, (Nov. 2001), 1684-1688.
Li, X., et al., “Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein e-null mice”, Circulation, Journal of the American Heart Association, 110, (2004), 1701-1705.
Linsel-Nitschke, P., et al., “HDL as a target in the treatment of atherosclerotic cardiovascular disease”, Nature Reviews Drug Discovery, 4(10), (2005), 193-205, Abstract.
Natarajan, P., et al., “Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1”, Journal of Biological Chemistry (JBC), 279(23), (2004), 24044-24052.
Navab, M., et al., “Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal”, Current Opinion in Lipidology, 15(6), (Dec. 2004), 645-649, Abstract.
Nissen, S. E., et al., “Effect of recombinant ApoA-I milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial”, JAMA, 290(17), (Nov. 2003), 2292-2300.
Panagotopulos, S. E., et al., “The role of apolipoprotein A-I helix 10 in apolipoprotein-mediated cholesterol efflux via the ATP-binding cassette transporter ABCA1”, Journal of Biological Chemistry, 277(42), (2002), 39477-39484.
Rader, D. J., “High-density lipoproteins and atherosclerosis”, American Journal of Cardiology, 90(8), (Oct. 2002), 62-80.
Shah, P. K., et al., “Effects of recombinant apolipoprotein A-Imilano on aortic atherosclerosis in apolipoprotein E-deficient mice”, Circulation, Journal of the American Heart Association, 97, (1998), 780-785.
Shah, P. K., et al., “High-dose recombinant apolipoprotein A-I milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization”, Circulation, Journal of the American Heart Association, 103, (2001), 3047-3050.
Vedhachalam, C., et al., “Influence of ApoA-I structure on the ABCA1-mediated efflux of cellular lipids”, Journal of Biological Chemistry (JBC), 279(48), (2004), 49931-49939.
Definition of derivative and analog from cancerweb.ncl.ac.uk/cgi-bin/omd?query=derivative, (Jul. 7, 2005), 5 pages.
“Designing Customs Peptides”, SIGMA Genosys, www.sigma-genosys.com/peptide—design.asp, (Dec. 16, 2004), 2 pages.
Abbott Cardiovascular Systems, Non Final Office Action dated Jun. 1, 2009 for U.S. Appl. No. 11/946,028.
Berendsen, H., “A glimpse of the holy grail?”, Science, vol. 282, www.sciencemag.org, (Oct. 1998), 642-643.
Bradley, et al., “Limits of cooperativity in a structurally modular protein: response of the notch ankyrin domain to analogous alanine substitutions in each repeat”, J. Mol. Biol., 324, (2002), 373-386.
Ngo, J. T., et al., “Computational complexity, protein structure prediction, and the levinthal paradox”, The Protein Folding Problem and Tertiary Structure Prediction, Birkhauser Boston, (1994), 491-495.
Rudin
Astafieva Irina
Bright Rachel
Consigny Paul M.
Davalian Dariush
Hossainy Syed Fayaiz Ahmed
Abbott Cardiovascular Systems Inc.
Blakely , Sokoloff, Taylor & Zafman LLP
Desai Anand U
LandOfFree
Sustained release of Apo A-I mimetic peptides and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release of Apo A-I mimetic peptides and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release of Apo A-I mimetic peptides and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2724409